Company Description
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide.
It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration.
The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services.
The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011.
Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 146 |
| CEO | Ms. Vered Caplan M.Sc. |
Contact Details
Address: 20271 Goldenrod Lane Germantown, Maryland 20876 United States | |
| Phone | (480) 659-6404 |
| Website | orgenesis.com |
Stock Details
| Ticker Symbol | ORGS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001460602 |
| CUSIP Number | 68619K204 |
| ISIN Number | US68619K2042 |
| Employer ID | 98-0583166 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vered Caplan M.Sc. | Chairperson of the Board, Chief Executive Officer and President |
| Prof. Sarah Ferber Ph.D. | Founder and Chief Scientific Officer |
| Victor Miller | Chief Financial Officer |
| Pierre Lammeretz | Interim Chief Operating Officer |
| Dr. Shimon Hassin Ph.D. | Chief Technology Officer |
| Evan Fishman | Chief Financial Officer of Orgenesis Biotech |
| Joseph Carpinelli | Chief Financial Officer of Octomera |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 12, 2024 | 8-K | Current Report |
| Jul 12, 2024 | 8-K | Current Report |
| Jul 9, 2024 | 8-K | Current Report |
| Jul 8, 2024 | 8-K | Current Report |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 424B3 | Prospectus |
| Jun 13, 2024 | EFFECT | Notice of Effectiveness |
| Jun 11, 2024 | 8-K | Current Report |
| Jun 11, 2024 | UPLOAD | Filing |